Pharmaceutical Industry Reports Biologics Market | Page 2

REPORT DESCRIPTION
Biologics Market – Overview
The biologics market size is expected to boost owing to the increasing product pipeline from different companies
like Merck and Co., Pfizer, Glaxosmithkline. Pfizer has a strong product pipeline for 2019 of biologics,
biosimilars, vaccines and small molecules. 35 products are in phase 1, 28 are in phase 2 and 26 are in phase 3 and
11 products are in the process of registration. Total 100 products are in trial phase. Most recent approval by Pfizer
is DAURISMO (glasdegib) in U.S. for adult patients with newly-diagnosed acute myeloid leukemia for whom
intensive chemotherapy is not an option.
Furthermore, the biologics market revenue is growing because of increasing number of Food and Drug
Administration (FDA) approvals for new biologic medicines for treatment of rare diseases. For instance, in 2017
US FDA approved 46 biologics and in December 2017, GlaxoSmithKline’s biologic Nucala was approved for the
treatment of a rare disease called eosinophilic granulomatosis, with polyangiitis (EPGA).
Biological products include a wide range of products such as vaccines, blood and blood components, allergenic,
somatic cells, gene therapy, tissues, and recombinant therapeutic proteins. Many biologics are produced using
recombinant DNA technology. Biologics are the best used drugs for genetic disorders. New technologies, novel
therapies are emerging for the manufacturing of new biologics which holds a prominent future for biologics
market.